A detailed history of Accredited Investors Inc. transactions in Amgen Inc stock. As of the latest transaction made, Accredited Investors Inc. holds 2,123 shares of AMGN stock, worth $611,148. This represents 0.04% of its overall portfolio holdings.

Number of Shares
2,123
Previous 8,834 75.97%
Holding current value
$611,148
Previous $2.85 Million 75.97%
% of portfolio
0.04%
Previous 0.07%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

SELL
$309.38 - $337.38 $2.08 Million - $2.26 Million
-6,711 Reduced 75.97%
2,123 $684,000
Q3 2024

Nov 05, 2024

BUY
$309.38 - $337.38 $2.08 Million - $2.27 Million
6,714 Added 316.7%
8,834 $2.85 Million
Q2 2024

Jul 19, 2024

BUY
$262.75 - $319.31 $1,051 - $1,277
4 Added 0.19%
2,120 $662,000
Q1 2024

May 14, 2024

BUY
$268.87 - $324.56 $182,293 - $220,051
678 Added 47.15%
2,116 $601,000
Q4 2023

Feb 07, 2024

SELL
$255.7 - $288.46 $8,438 - $9,519
-33 Reduced 2.24%
1,438 $414,000
Q3 2023

Nov 07, 2023

BUY
$218.65 - $271.46 $437 - $542
2 Added 0.14%
1,471 $395,000
Q2 2023

Aug 03, 2023

SELL
$214.27 - $253.37 $15,855 - $18,749
-74 Reduced 4.8%
1,469 $326,000
Q1 2023

Apr 24, 2023

BUY
$225.79 - $275.2 $451 - $550
2 Added 0.13%
1,543 $373,000
Q4 2022

Feb 07, 2023

BUY
$229.03 - $291.01 $8,245 - $10,476
36 Added 2.39%
1,541 $404,000
Q3 2022

Nov 08, 2022

SELL
$224.46 - $253.15 $63,522 - $71,641
-283 Reduced 15.83%
1,505 $339,000
Q2 2022

Jul 21, 2022

BUY
$230.71 - $256.74 $113,740 - $126,572
493 Added 38.07%
1,788 $435,000
Q1 2022

May 06, 2022

SELL
$219.27 - $242.57 $2,192 - $2,425
-10 Reduced 0.77%
1,295 $313,000
Q4 2021

Jan 31, 2022

BUY
$198.88 - $227.6 $2,585 - $2,958
13 Added 1.01%
1,305 $293,000
Q3 2021

Nov 12, 2021

SELL
$212.27 - $248.7 $12,311 - $14,424
-58 Reduced 4.3%
1,292 $275,000
Q2 2021

Jul 30, 2021

BUY
$233.58 - $259.14 $48,584 - $53,901
208 Added 18.21%
1,350 $329,000
Q1 2021

Apr 16, 2021

SELL
$221.91 - $258.6 $36,837 - $42,927
-166 Reduced 12.69%
1,142 $284,000
Q4 2020

Feb 11, 2021

BUY
$216.38 - $257.67 $53,878 - $64,159
249 Added 23.51%
1,308 $301,000
Q3 2020

Nov 05, 2020

BUY
$234.65 - $260.95 $21,587 - $24,007
92 Added 9.51%
1,059 $269,000
Q2 2020

Jul 29, 2020

SELL
$197.81 - $242.74 $144,796 - $177,685
-732 Reduced 43.08%
967 $228,000
Q1 2020

May 15, 2020

SELL
$182.24 - $241.7 $364 - $483
-2 Reduced 0.12%
1,699 $344,000
Q3 2019

Nov 14, 2019

SELL
$174.11 - $208.62 $23,853 - $28,580
-137 Reduced 7.45%
1,701 $329,000
Q2 2019

Aug 13, 2019

SELL
$166.7 - $195.41 $4,834 - $5,666
-29 Reduced 1.55%
1,838 $0
Q1 2019

Apr 17, 2019

BUY
$180.87 - $203.88 $56,250 - $63,406
311 Added 19.99%
1,867 $355,000
Q3 2018

Oct 23, 2018

SELL
$185.29 - $208.89 $13,896 - $15,666
-75 Reduced 4.6%
1,556 $323,000
Q2 2018

Jul 31, 2018

SELL
$166.05 - $186.51 $6,309 - $7,087
-38 Reduced 2.28%
1,631 $301,000
Q1 2018

Apr 18, 2018

BUY
$169.43 - $198.0 $17,620 - $20,592
104 Added 6.65%
1,669 $285,000
Q4 2017

Jan 17, 2018

BUY
$168.79 - $188.59 $1,519 - $1,697
9 Added 0.58%
1,565 $272,000
Q3 2017

Oct 30, 2017

BUY
$167.29 - $191.0 $260,303 - $297,196
1,556
1,556 $290,000

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $154B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Accredited Investors Inc. Portfolio

Follow Accredited Investors Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Accredited Investors Inc., based on Form 13F filings with the SEC.

News

Stay updated on Accredited Investors Inc. with notifications on news.